Clinical Manifestations and Ophthalmic Outcomes of Leukemic Retinopathy and Optic Neuropathy in Patients With Acute Leukemia
Investigative Ophthalmology & Visual Science · 2025
DOI: 10.1167/iovs.66.11.2 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, 2025. Written by Chi-Ying Chen and 12 co-authors. Institution: Department of Medical Education, National Taiwan University Hospital, Taipei, Taiwan. Major MEDLINE topics: Visual Acuity, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Optic Nerve Diseases. Cited 6 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Purpose
To investigate the clinical manifestations and visual outcomes of leukemic retinopathy and optic neuropathy (LRON) in patients with acute leukemia.
Methods
We recruited 276 patients with acute leukemia, 55 of whom had LRON. The ophthalmic measurements, treatment courses, laboratory data, and molecular profiling were retrospectively collected.
Results
Patients with LRON were classified as type 1, type 2a, type 2b, and type 3. All patients with type 3 LRON had acute lymphoblastic leukemia (ALL), while the other types of LRON mainly occurred in patients with acute myeloid leukemia (AML). Patients with type 2b and type 3 LRON had worse initial best-corrected visual acuity (BCVA); none of the patients with type 3 LRON had recovery of BCVA during follow-up. The patients with AML with LRON were more likely to undergo hematopoietic stem cell transplantation (P < 0.001); their leukemic blasts more frequently expressed CD7 (P = 0.004) and CD38 (P = 0.048) and harbored DNMT3A (P = 0.017) and IDH1 (P = 0.041) mutations. Notably, the co-occurrence of DNMT3A, IDH1, and TET2 mutations was associated with a particularly high risk of LRON (odds ratio = 16.41). The patients with ALL with type 3 LRON had higher rates of central nervous system involvement (P = 0.041) and relapsed leukemia (P = 0.007). Nevertheless, the presence of LRON did not significantly affect survival in acute leukemia.
Conclusions
We characterized distinct clinical, genetic features and visual outcomes across LRON subtypes. Our study highlights the importance of prompt ophthalmic consultation and patient education regarding visual symptoms in acute leukemia.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Department of Medical Education, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Biostatistics and Health Data Science, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, United States.
- Department of Biology, University of British Columbia, British Columbia, Canada.
- Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Cite
APA
Chen, C. Y., Jhang, J. P., Lai, Y. J., Lin, C. W., Chou, E. T., Lin, C. C., Tsai, X. C., Tien, F. M., Hou, H. A., Tien, H. F., Chou, W. C., Yao, C. Y., & Chen, T. C. (2025). Clinical Manifestations and Ophthalmic Outcomes of Leukemic Retinopathy and Optic Neuropathy in Patients With Acute Leukemia. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.66.11.2
Vancouver
Chen CY, Jhang JP, Lai YJ, Lin CW, Chou ET, Lin CC, et al. Clinical Manifestations and Ophthalmic Outcomes of Leukemic Retinopathy and Optic Neuropathy in Patients With Acute Leukemia. Investigative Ophthalmology & Visual Science. 2025. doi:10.1167/iovs.66.11.2
BibTeX
@article{Chen2025,
author = {Chen, Chi-Ying and Jhang, Jia-Pang and Lai, Ying-Ju and Lin, Chao-Wen and Chou, Evelyn Ting-Hsuan and Lin, Chien-Chin and Tsai, Xavier Cheng-Hong and Tien, Feng-Ming and Hou, Hsin-An and Tien, Hwei-Fang and Chou, Wen-Chien and Yao, Chi-Yuan and Chen, Ta-Ching},
title = {Clinical Manifestations and Ophthalmic Outcomes of Leukemic Retinopathy and Optic Neuropathy in Patients With Acute Leukemia},
journal = {Investigative Ophthalmology & Visual Science},
year = {2025},
doi = {10.1167/iovs.66.11.2}
}
EUVIMED